# The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema

> **NCT06655428** · NA · RECRUITING · sponsor: **Morair Medtech, LLC** · enrollment: 30 (estimated)

## Conditions studied

- Emphysema or COPD
- Emphysema
- Emphysema, Pulmonary
- COPD
- COPD (Chronic Obstructive Pulmonary Disease)

## Interventions

- **DEVICE:** Endobronchial Therman Liquid Ablation (ETLA)

## Key facts

- **NCT ID:** NCT06655428
- **Lead sponsor:** Morair Medtech, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2026-02
- **Final completion:** 2026-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06655428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06655428, "The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06655428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*